Download PDF
Semin Thromb Hemost 2016; 42(02): 118-124
DOI: 10.1055/s-0035-1564833
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelet Transfusion and Thrombosis: More Questions than Answers

Amy E. Schmidt
1   Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
,
Majed A. Refaai
1   Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
,
Neil Blumberg
1   Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2015 (online)

    Permissions and Reprints

Abstract

Platelets perform a vital role in hemostasis and their role in inflammation is becoming increasingly evident. Blood transfusion is the most common procedure performed in hospitals and platelet transfusions comprise a significant proportion. Over the past few decades, retrospective studies and randomized clinical trials have demonstrated that blood transfusion is more harmful than previously thought and is associated with numerous complications, such as transfusion-associated lung injury, transfusion-associated cardiac overload, transfusion-associated immune modulation, and infectious diseases such as human immunodeficiency virus, hepatitis C virus, and hepatitis B virus. Recent data suggest an association between platelet transfusion and thrombosis. This review will highlight the mechanistic issues that may be relevant to the epidemiologic associations of platelet transfusion with thrombosis and mortality in critically ill patients.

Keywords

platelets - microparticles - thrombosis - transfusion
 

  • References

  • 1 Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168 (21) 2377-2381
    CrossrefPubMedGoogle Scholar
  • 2 de Boer MT, Christensen MC, Asmussen M , et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008; 106 (1) 32-44
    CrossrefPubMedGoogle Scholar
  • 3 Cornet AD, Klein LJ, Groeneveld AB. Coronary stent occlusion after platelet transfusion: a case series. J Invasive Cardiol 2007; 19 (10) E297-E299
    PubMedGoogle Scholar
  • 4 Shin HS, Kang TS. A case of late stent thrombosis following platelet transfusion in a patient with aplastic anemia. Korean Circ J 2012; 42 (1) 54-57
    CrossrefPubMedGoogle Scholar
  • 5 Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125 (9) 1470-1476
    CrossrefPubMedGoogle Scholar
  • 6 Solomon C, Traintinger S, Ziegler B , et al. Platelet function following trauma. A multiple electrode aggregometry study. Thromb Haemost 2011; 106 (2) 322-330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kutcher ME, Redick BJ, McCreery RC , et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012; 73 (1) 13-19
    CrossrefPubMedGoogle Scholar
  • 8 Briggs A, Gates JD, Kaufman RM, Calahan C, Gormley WB, Havens JM. Platelet dysfunction and platelet transfusion in traumatic brain injury. J Surg Res 2015; 193 (2) 802-806
    CrossrefPubMedGoogle Scholar
  • 9 Windeløv NA, Sørensen AM, Perner A , et al. Platelet aggregation following trauma: a prospective study. Blood Coagul Fibrinolysis 2014; 25 (1) 67-73
    CrossrefPubMedGoogle Scholar
  • 10 Cap A, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia 2015; 70 (Suppl. 01) 96-101 , e32–e34
    CrossrefPubMedGoogle Scholar
  • 11 Etulain J, Negrotto S, Carestia A , et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 2012; 107 (1) 99-110
    PubMedGoogle Scholar
  • 12 Sinauridze EI, Kireev DA, Popenko NY , et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97 (3) 425-434
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264 (29) 17049-17057
    PubMedGoogle Scholar
  • 14 Wiedmer T, Shattil SJ, Cunningham M, Sims PJ. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 1990; 29 (3) 623-632
    CrossrefPubMedGoogle Scholar
  • 15 Italiano Jr JE, Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010; 17 (6) 578-584
    CrossrefPubMedGoogle Scholar
  • 16 Zwaal RF, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180 (1) 1-8
    CrossrefPubMedGoogle Scholar
  • 17 Goubran HA, Burnouf T, Stakiw J, Seghatchian J. Platelet microparticle: a sensitive physiological “fine tuning” balancing factor in health and disease. Transfus Apheresis Sci 2015; 52 (1) 12-18
    CrossrefPubMedGoogle Scholar
  • 18 Miyazaki Y, Nomura S, Miyake T , et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88 (9) 3456-3464
    PubMedGoogle Scholar
  • 19 Holme PA, Orvim U, Hamers MJ , et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17 (4) 646-653
    CrossrefPubMedGoogle Scholar
  • 20 Chow TW, Hellums JD, Thiagarajan P. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. J Lab Clin Med 2000; 135 (1) 66-72
    CrossrefPubMedGoogle Scholar
  • 21 Flaumenhaft R, Dilks JR, Richardson J , et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113 (5) 1112-1121
    CrossrefPubMedGoogle Scholar
  • 22 Gyulkhandanyan AV, Mutlu A, Freedman J, Leytin V. Markers of platelet apoptosis: methodology and applications. J Thromb Thrombolysis 2012; 33 (4) 397-411
    CrossrefPubMedGoogle Scholar
  • 23 Bassé F, Gaffet P, Bienvenüe A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: are vesicles shed by filopod fragmentation?. Biochim Biophys Acta 1994; 1190 (2) 217-224
    CrossrefPubMedGoogle Scholar
  • 24 Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80 (1) 198-205
    CrossrefPubMedGoogle Scholar
  • 25 Lee YJ, Jy W, Horstman LL , et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72 (4) 295-304
    CrossrefPubMedGoogle Scholar
  • 26 Sims PJ, Wiedmer T. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++ -dependent exocytotic elimination of C5b-9 pores. Blood 1986; 68 (2) 556-561
    PubMedGoogle Scholar
  • 27 Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 2013; 20 (5) 472-477
    CrossrefPubMedGoogle Scholar
  • 28 Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 1992; 41 (Suppl. 02) 86-91
    CrossrefPubMedGoogle Scholar
  • 29 Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res 2009; 45 (2–3) 251-260
    CrossrefPubMedGoogle Scholar
  • 30 Nomura S, Okamae F, Abe M , et al. Platelets expressing P-selectin and platelet-derived microparticles in stored platelet concentrates bind to PSGL-1 on filtrated leukocytes. Clin Appl Thromb Hemost 2000; 6 (4) 213-221
    CrossrefPubMedGoogle Scholar
  • 31 Prasad KS, Andre P, Yan Y, Phillips DR. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10 (5) 356-361
    CrossrefPubMedGoogle Scholar
  • 32 Siljander P, Carpen O, Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996; 87 (11) 4651-4663
    CrossrefPubMedGoogle Scholar
  • 33 Matijevic N, Wang YW, Kostousov V, Wade CE, Vijayan KV, Holcomb JB. Decline in platelet microparticles contributes to reduced hemostatic potential of stored plasma. Thromb Res 2011; 128 (1) 35-41
    CrossrefPubMedGoogle Scholar
  • 34 Muellner SK, Haut ER, Streiff MB, Holcomb JB, Cotton BA. ABO blood group as a potential risk factor for venous thromboembolism in acutely injured patients. Thromb Haemost 2011; 105 (1) 5-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Windeløv NA, Johansson PI, Sørensen AM , et al. Low level of procoagulant platelet microparticles is associated with impaired coagulation and transfusion requirements in trauma patients. J Trauma Acute Care Surg 2014; 77 (5) 692-700
    CrossrefPubMedGoogle Scholar
  • 36 Matijevic N, Wang YW, Wade CE , et al; PROMMTT Study Group. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res 2014; 134 (3) 652-658
    CrossrefPubMedGoogle Scholar
  • 37 Lannan KL, Phipps RP, White RJ. Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today 2014; 19 (8) 1230-1235
    CrossrefPubMedGoogle Scholar
  • 38 Damås JK, Otterdal K, Yndestad A , et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004; 110 (8) 999-1005
    CrossrefPubMedGoogle Scholar
  • 39 Diehl P, Aleker M, Helbing T , et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg 2010; 11 (2) 133-137
    CrossrefPubMedGoogle Scholar
  • 40 Nadaud S, Poirier O, Girerd B , et al. Small platelet microparticle levels are increased in pulmonary arterial hypertension. Eur J Clin Invest 2013; 43 (1) 64-71
    CrossrefPubMedGoogle Scholar
  • 41 Bakouboula B, Morel O, Faure A , et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177 (5) 536-543
    CrossrefPubMedGoogle Scholar
  • 42 Burnouf T, Goubran HA, Chou ML, Devos D, Radosevic M. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Rev 2014; 28 (4) 155-166
    CrossrefPubMedGoogle Scholar
  • 43 Morelli VM, De Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005; 3 (1) 183-185
    CrossrefPubMedGoogle Scholar
  • 44 Morelli VM, de Visser MC, van Tilburg NH , et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97 (4) 534-541
    PubMedGoogle Scholar
  • 45 Franchini M, Lippi G. Relative risks of thrombosis and bleeding in different ABO blood groups. Semin Thromb Hemost 2016; 42 (2) 112-117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Talbot S, Wakley EJ, Ryrie D, Langman MJ. ABO blood-groups and venous thromboembolic disease. Lancet 1970; 1 (7659) 1257-1259
    PubMedGoogle Scholar
  • 47 Tirado I, Mateo J, Soria JM , et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93 (3) 468-474
    PubMedGoogle Scholar
  • 48 Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69 (6) 1691-1695
    CrossrefPubMedGoogle Scholar
  • 49 Gallinaro L, Cattini MG, Sztukowska M , et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111 (7) 3540-3545
    CrossrefPubMedGoogle Scholar
  • 50 Nossent AY, VAN Marion V, VAN Tilburg NH , et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4 (12) 2556-2562
    CrossrefPubMedGoogle Scholar
  • 51 O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22 (2) 335-341
    CrossrefPubMedGoogle Scholar
  • 52 Wiggins KL, Smith NL, Glazer NL , et al. ABO genotype and risk of thrombotic events and hemorrhagic stroke. J Thromb Haemost 2009; 7 (2) 263-269
    CrossrefPubMedGoogle Scholar
  • 53 Nydegger UE, Wuillemin WA, Julmy F, Meyer BJ, Carrel TP. Association of ABO histo-blood group B allele with myocardial infarction. Eur J Immunogenet 2003; 30 (3) 201-206
    CrossrefPubMedGoogle Scholar
  • 54 von Beckerath N, Koch W, Mehilli J , et al. ABO locus O1 allele and risk of myocardial infarction. Blood Coagul Fibrinolysis 2004; 15 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 55 Reilly MP, Li M, He J , et al; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377 (9763) 383-392
    CrossrefPubMedGoogle Scholar
  • 56 Barbalic M, Dupuis J, Dehghan A , et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010; 19 (9) 1863-1872
    CrossrefPubMedGoogle Scholar
  • 57 Qi L, Cornelis MC, Kraft P , et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 2010; 19 (9) 1856-1862
    CrossrefPubMedGoogle Scholar
  • 58 Zhou S, Welsby I. Is ABO blood group truly a risk factor for thrombosis and adverse outcomes?. World J Cardiol 2014; 6 (9) 985-992
    CrossrefPubMedGoogle Scholar
  • 59 Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med 2005; 22 (12) 1657-1662
    CrossrefPubMedGoogle Scholar
  • 60 Vidal C, Spaulding C, Picard F , et al. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86 (3) 784-790
    PubMedGoogle Scholar
  • 61 Suades R, Padró T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108 (6) 1208-1219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Refaai MA, Carter J, Henrichs KF , et al. Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B. Transfusion 2013; 53 (2) 382-393
    CrossrefPubMedGoogle Scholar
  • 63 Refaai MA, Fialkow LB, Heal JM , et al. An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang 2011; 101 (1) 55-60
    CrossrefPubMedGoogle Scholar
  • 64 Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutiérrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apheresis Sci 2015; 52 (1) 19-34
    CrossrefPubMedGoogle Scholar
  • 65 McCullough J, Vesole DH, Benjamin RJ , et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104 (5) 1534-1541
    CrossrefPubMedGoogle Scholar
  • 66 Kerkhoffs JL, van Putten WL, Novotny VM , et al; Dutch - Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150 (2) 209-217
    PubMedGoogle Scholar
  • 67 Lozano M, Knutson F, Tardivel R , et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153 (3) 393-401
    CrossrefPubMedGoogle Scholar
  • 68 Perez-Pujol S, Tonda R, Lozano M , et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45 (6) 911-919
    CrossrefPubMedGoogle Scholar
  • 69 Zeddies S, De Cuyper IM, van der Meer PF , et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54 (9) 2292-2300
    CrossrefPubMedGoogle Scholar
  • 70 Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apheresis Sci 2012; 46 (2) 221-229
    CrossrefPubMedGoogle Scholar
  • 71 Zhu M, Xu W, Wang BL, Su H. Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients. Transfus Med Hemother 2014; 41 (3) 189-196
    CrossrefPubMedGoogle Scholar
  • 72 Seghatchian J, Krailadsiri P. Platelet storage lesion and apoptosis: are they related?. Transfus Apheresis Sci 2001; 24 (1) 103-105
    CrossrefPubMedGoogle Scholar
  • 73 Murphy WG, Coakley P. Testing platelet components for bacterial contamination. Transfus Apheresis Sci 2011; 45 (1) 69-74
    CrossrefPubMedGoogle Scholar
  • 74 Reddoch KM, Pidcoke HF, Montgomery RK , et al. Hemostatic function of apheresis platelets stored at 4°C and 22°C. Shock 2014; 41 (Suppl. 01) 54-61
    CrossrefPubMedGoogle Scholar
  • 75 Ayukawa O, Nakamura K, Kariyazono H , et al. Enhanced platelet responsiveness due to chilling and its relation to CD40 ligand level and platelet-leukocyte aggregate formation. Blood Coagul Fibrinolysis 2009; 20 (3) 176-184
    CrossrefPubMedGoogle Scholar
  • 76 Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. Transfusion 1976; 16 (1) 8-12
    PubMedGoogle Scholar
  • 77 Valeri CR. Circulation and hemostatic effectiveness of platelets stored at 4 C or 22 C: studies in aspirin-treated normal volunteers. Transfusion 1976; 16 (1) 20-23
    PubMedGoogle Scholar
  • 78 Becker GA, Tuccelli M, Kunicki T, Chalos MK, Aster RH. Studies of platelet concentrates stored at 22 C nad 4 C. Transfusion 1973; 13 (2) 61-68
    CrossrefPubMedGoogle Scholar
  • 79 Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage. N Engl J Med 1969; 280 (20) 1094-1098
    CrossrefPubMedGoogle Scholar
  • 80 Khuri SF, Healey N, MacGregor H , et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 117 (1) 172-183 , discussion 183–184
    CrossrefPubMedGoogle Scholar
  • 81 Dumont LJ, Cancelas JA, Dumont DF , et al. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion 2013; 53 (1) 128-137
    CrossrefPubMedGoogle Scholar
  • 82 Johnson L, Reid S, Tan S, Vidovic D, Marks DC. PAS-G supports platelet reconstitution after cryopreservation in the absence of plasma. Transfusion 2013; 53 (10) 2268-2277
    PubMedGoogle Scholar
  • 83 Johnson LN, Winter KM, Reid S, Hartkopf-Theis T, Marks DC. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. Cryobiology 2011; 62 (2) 100-106
    CrossrefPubMedGoogle Scholar
  • 84 Valeri CR, Macgregor H, Ragno G. Correlation between in vitro aggregation and thromboxane A2 production in fresh, liquid-preserved, and cryopreserved human platelets: effect of agonists, pH, and plasma and saline resuspension. Transfusion 2005; 45 (4) 596-603
    CrossrefPubMedGoogle Scholar
  • 85 Johnson L, Coorey CP, Marks DC. The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion 2014; 54 (8) 1917-1926
    CrossrefPubMedGoogle Scholar